GSA Capital Partners LLP Invests $977,000 in Urogen Pharma $URGN
GSA Capital Partners LLP has acquired a new stake of 48,964 shares in Urogen Pharma (NASDAQ:URGN) valued at approximately $977,000, as disclosed in its latest 13F filing. The investment represents about 0.11% ownership in Urogen Pharma. Insiders Jason Drew Smith and Mark Schoenberg recently sold shares, while institutional investors collectively own 91.29% of the company.
How Urogen Pharma Ltd. (URGN) Affects Rotational Strategy Timing
This article analyzes Urogen Pharma Ltd. (URGN) for rotational strategy timing, highlighting weak near-term sentiment but strong mid and long-term outlooks. It identifies an exceptional risk-reward setup and provides three distinct AI-generated trading strategies tailored for different risk profiles and holding periods, focusing on position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis with key support and resistance levels.
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target
UroGen Pharma's CEO, Liz Barrett, discussed the commercial momentum of their bladder cancer therapy, ZUSDURI, targeting a billion-plus peak sales. The company reported early revenue success and accelerated uptake since a permanent J-code took effect on January 1, attributing it to 100% reimbursement and fewer administrative hurdles. ZUSDURI offers a non-surgical alternative for recurrent low-grade intermediate-risk NMIBC patients, showing high complete response rates and significant durability.
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares
Urogen Pharma's General Counsel, Jason Drew Smith, sold 7,479 shares of URGN stock on February 3rd for over $147,000, reducing his stake by 12.72%. Following the sale, he now owns 51,326 shares valued at approximately $1 million. The stock traded down about 2.4% recently and analysts currently maintain a "Moderate Buy" rating with an average target price of $33.00.
Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN)
UroGen Pharma Ltd. (NASDAQ:URGN), a loss-making biotech company, is nearing profitability according to analysts. The consensus from 8 American Biotech analysts projects the company to breakeven in 2026 and generate positive profits of US$89m in 2027, requiring an optimistic 58% year-on-year growth. The article also highlights the company's current negative equity on its balance sheet.
UroGen Pharma CMO Schoenberg sells $145k in shares
Mark Schoenberg, CMO of UroGen Pharma Ltd, sold 7,373 shares for $145,174 to cover tax obligations from restricted stock units. This transaction leaves him with 144,985 shares. The company recently reported a miss on both EPS and revenue for Q3 2025, with no significant updates on mergers or analyst ratings.
(URGN) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Urogen Pharma Ltd. (NASDAQ: URGN), highlighting a strong bullish sentiment across all time horizons. It details specific AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with their entry/target/stop-loss points, reflecting a robust risk-reward setup. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
UroGen Pharma CMO Schoenberg sells $145k in shares By Investing.com
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 7,373 shares of the company for $145,174 to cover tax obligations. Following this, he still owns 144,985 shares. This transaction occurred shortly after UroGen Pharma reported a miss in both EPS and revenue for its third quarter of 2025.
UroGen Pharma CMO Schoenberg sells $145k in shares
Mark Schoenberg, UroGen Pharma's Chief Medical Officer, sold 7,373 shares of the company's ordinary shares for a total of $145,174 to cover withholding tax obligations. Following this transaction, Schoenberg directly owns 144,985 shares. This sale comes after UroGen Pharma reported a miss in both EPS and revenue for its third-quarter 2025 earnings.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd. will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026, where the management will participate in a fireside chat and investor meetings. The company, which specializes in innovative solutions for urothelial and specialty cancers, will also make a webcast of the event available on its corporate website.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd. will be presenting at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026, where management will participate in a fireside chat and one-on-one investor meetings. The biotech company focuses on developing innovative solutions for urothelial and specialty cancers, utilizing its proprietary RTGel® reverse-thermal hydrogel technology. A webcast of the presentation will be available on their corporate website for approximately 90 days.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd. announced that its management will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12, 2026. The presentation will be a fireside chat on February 12th at 2:30 PM ET, with 1x1 investor meetings, and will also be webcast on UroGen's corporate website. UroGen Pharma is a biotech company focused on developing innovative solutions for urothelial and specialty cancers.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd. announced it will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12, 2026. The biotech company focuses on developing innovative solutions for urothelial and specialty cancers, utilizing its RTGel® reverse-thermal hydrogel platform. A webcast of the presentation will be available on UroGen's corporate website.
Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages
Urogen Pharma (NASDAQ:URGN) has received an average "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $33.00. The company reported EPS of ($0.69) for its last quarter, beating estimates, but revenue of $27.48 million missed forecasts. Insiders own 4.7% of the company, and institutional investors hold approximately 91.29%.
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $32
Guggenheim analyst Michael Schmidt has reiterated a "Buy" rating for UroGen Pharma Ltd (URGN.US) and maintained a target price of $32. The analyst has a 57.1% success rate and an average return of 28.1% over the past year, according to TipRanks data. This information is intended for informational purposes only and is not an investment recommendation.
Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN
Privium Fund Management B.V. significantly increased its stake in Urogen Pharma (NASDAQ:URGN) by 82.7% in the third quarter, now holding 196,622 shares valued at approximately $3.92 million. This makes Urogen Pharma its 23rd-largest holding. The article also notes recent insider selling by Mark Schoenberg and outlines analyst ratings, which currently average a "Moderate Buy" with a consensus price target of $33.00, despite a recent stock price decline.
Responsive Playbooks and the URGN Inflection
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN), highlighting a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies a mid-channel oscillation pattern and presents an exceptional 75.8:1 risk-reward setup targeting a 23.8% gain against a 0.3% risk. The analysis includes AI-generated trading strategies for various risk profiles and covers multi-timeframe signal analysis with support and resistance levels.
URGN: Analyst Jason Kolbert Maintains 'Buy' Rating with $33 Pric
D. Boral Capital analyst Jason Kolbert has reiterated a 'Buy' rating for UroGen Pharma (URGN) with a $33.00 price target, reflecting consistent confidence in the company's growth potential. This rating aligns with other analysts who see significant upside, with an average target price of $35.25. UroGen Pharma, a clinical-stage biotechnology firm, specializes in solutions for urothelial and specialty cancers, with key products like Jelmyto and investigational candidate UGN-102.
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital
D. Boral Capital reiterated a "Buy" rating for Urogen Pharma (NASDAQ:URGN) with a $33 target price, signifying a potential 65% upside. This aligns with the broader market consensus of a "Moderate Buy" for the stock. Despite missing revenue expectations, Urogen Pharma beat its Q3 EPS estimates, and the company has seen recent insider selling but significant institutional investor activity.
UroGen drops 20% as FDA releases docs in advance of AdCom meeting
UroGen Pharma's stock dropped by 20% following the FDA's release of briefing documents for its AdCom meeting regarding UGN-102. The documents outlined concerns about the trial design's impact on blinding, the chosen active comparator, and the generalizability of results. The AdCom meeting is scheduled for January 31, 2026.
JELMYTO shows promise in long-term cancer treatment study
The article reports on the promising long-term results of JELMYTO in a cancer treatment study. This suggests the drug could be an effective and durable option for patients. Further details about the specific cancer type and study outcomes would be needed for a more comprehensive understanding.
Understanding the Setup: (URGN) and Scalable Risk
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It provides institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis points to elevated downside risk due to a lack of additional long-term support signals.
Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.7% - Here's What Happened
Urogen Pharma (NASDAQ:URGN) shares dropped 6.7% on Tuesday, closing at $20.01 after trading as low as $20.02, with a significantly lower trading volume than average. The company's quarterly results were mixed, with an EPS of -$0.69 beating estimates but revenue of $27.48 million missing expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $33.00, despite recent stock and earnings performance.
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code
UroGen Pharma's shares are in focus after its bladder cancer therapy, ZUSDURI, received a permanent J code (J9282), effective January 1, 2026, which is expected to simplify reimbursement and drive further growth. The article suggests UroGen Pharma is currently undervalued at US$21.45, with an analyst price target of US$35.25, supported by the shift towards minimally invasive treatments and ZUSDURI's long-term durability data. However, potential risks include operating losses and equity dilution if product uptake or payer access falls short.
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code
UroGen Pharma's shares are in focus after its bladder cancer therapy, ZUSDURI, received a permanent J code (J9282) effective January 1, 2026, which is expected to simplify reimbursement. Despite a significant 90-day share price return of 24.06% and a 1-year total shareholder return of 116.01%, the stock is trading at US$21.45 against an analyst target of US$35.25. The article suggests UroGen Pharma is currently undervalued with a fair value of $35.25, driven by ZUSDURI's alignment with industry trends towards minimally invasive therapies, but cautions about risks like operating losses and potential equity dilution.
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors
Several insiders at UroGen Pharma Ltd. (NASDAQ:URGN) sold shares over the past year, which could be a weak negative signal for investors, although no insider purchases were made. The sales included a significant amount from the Chief Medical Officer, Mark Schoenberg, at a price slightly below the current market value. Despite the selling, insiders still retain a 2.1% ownership in the company, worth about US$22 million, indicating some alignment with shareholder interests.
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors
Multiple insiders at UroGen Pharma (NASDAQ:URGN) sold shares in the past year, with one significant sale by the Chief Medical Officer for US$177k at a price below the current market value. While no insider buys were recorded, and the recent insider activity isn't explicitly concerning, a higher level of insider ownership (currently 2.1%) does suggest some alignment between management and shareholders. Investors are advised to consider insider transactions as a weak signal and to look into other financial indicators and risks.
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors
Multiple insiders at UroGen Pharma (NASDAQ:URGN) sold shares in the last year, with the Chief Medical Officer selling US$177k worth of shares below the current market price. While insider selling can be interpreted in various ways, a pattern of numerous insiders selling may raise concerns for investors. Despite the selling, insiders still own 2.1% of the company's shares.
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
UroGen Pharma Ltd. (URGN) shares dropped 44% after the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against the risk/benefit profile of UGN-102 due to concerns about its single-arm trial design. Hagens Berman has launched an investigation into potential securities law violations, questioning UroGen's disclosures regarding its communications with the FDA about the trial. The FDA had previously expressed concerns about the lack of a randomized trial and comparative safety data for UGN-102, a therapy for non-muscle invasive bladder cancer.
UroGen Pharma says permanent J Code for ZUSDURI now in effect
UroGen Pharma announced that ZUSDURI, a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, now has a permanent Healthcare Common Procedure Coding System Level II J Code (J9282). This new code, effective January 1, 2026, is expected to simplify billing and reimbursement, improving patient access to the therapy. The Centers for Medicare & Medicaid Services assigned the code to streamline processes in hospital outpatient and physician office settings.
New billing code aims to speed access to nonsurgical bladder cancer treatment
UroGen Pharma announced that the permanent HCPCS Level II J Code J9282 for ZUSDURI (mitomycin) intravesical solution became effective on January 1, 2026. This J Code is expected to streamline billing and reimbursement processes for ZUSDURI, the only FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), thereby improving patient access and reducing administrative delays. The announcement on January 5, 2026, was met with a moderate negative market reaction, with URGN stock declining by 2.55%.
Urogen Pharma (NASDAQ:URGN) Shares Down 6.5% - What's Next?
Urogen Pharma (NASDAQ:URGN) shares dropped 6.5% during mid-day trading on Monday, with the stock trading below its 50-day simple moving average. Despite the decline, analysts maintain a "Moderate Buy" consensus with an average price target of $33. The company recently reported earnings that beat estimates but missed revenue expectations, and institutional investors hold a significant portion of its shares.
D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)
D. Boral Capital has reaffirmed its "Buy" rating for Urogen Pharma (NASDAQ:URGN), setting a $33 price target, which suggests a 45% upside. The consensus from nine analysts is a "Moderate Buy" with an average target of $33. Urogen Pharma recently reported Q3 EPS of ($0.69), beating estimates, though revenue for the quarter missed expectations.
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
UroGen Pharma Ltd. announced the permanent Healthcare Common Procedure Coding System Level II J Code (J9282) for ZUSDURI™ (mitomycin) for intravesical solution became effective on January 1, 2026. This J Code aims to simplify billing and reimbursement for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) treatment, enhancing patient access by reducing administrative delays. The company and patient advocacy groups believe this will provide a clearer, more efficient path to timely care for patients with this highly recurrent disease.
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
UroGen Pharma Ltd. announced that a permanent J Code (J9282) for ZUSDURI™ (mitomycin) intravesical solution became effective on January 1, 2026, improving access for patients with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer. This code is expected to streamline billing and reimbursement processes, reducing administrative hurdles for timely patient treatment. ZUSDURI is the first and only FDA-approved nonsurgical chemoablative option for this condition, addressing a critical need for patients facing fear, uncertainty, and repeated procedures.
The Truth About UroGen Pharma (URGN): Is This Tiny Cancer Stock the Next Viral Game-Changer or a Total Trap?
UroGen Pharma (URGN) is a small biotech company focused on uro-oncology, with a marketed bladder and urinary tract cancer treatment. The stock presents high-risk, high-reward potential due to its commercial product, pipeline, and potential as an acquisition target. While not a meme stock yet, its binary events could generate significant social media attention.
The Technical Signals Behind (URGN) That Institutions Follow
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN) using AI models to provide institutional trading strategies. It highlights weak near-term sentiment but potential long-term strength, with resistance being tested. The analysis includes diverse trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal insights.
URGN: Small-Cap Biotech On A Knife Edge As Traders Weigh Risk, Cash And Uro-Oncology Data
UroGen Pharma's stock has seen a recent pullback after a strong fourth-quarter rebound, leaving investors to assess if it's a consolidation or a new downturn. The company faces scrutiny over its cash runway, uro-oncology data, and mixed Wall Street opinions, positioning URGN as a high-volatility investment. Its future hinges on commercial execution, pipeline progress, and financial management to convert scientific promise into sustainable revenue growth.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against UroGen, Strategy Incorporated, and Organon and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced that class action lawsuits have been filed against UroGen Pharma Ltd. (NASDAQ:URGN), Strategy Incorporated (NASDAQ:MSTR), and Organon & Co. (NYSE:OGN). The firm is encouraging investors in these companies to contact them to potentially serve as lead plaintiffs. The lawsuits allege that these companies made false and misleading statements to investors, leading to significant stock price declines.
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
Robbins LLP has reminded investors of a class action lawsuit against UroGen Pharma Ltd. (NASDAQ: URGN) for misrepresentations made between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen failed to conduct a proper trial for its lead drug candidate, UGN-102, which resulted in the FDA doubting its effectiveness and ultimately the Oncological Drugs Advisory Committee voting against its approval, causing significant stock price drops. Shareholders who qualify may participate as lead plaintiff in the class action.
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
Robbins LLP has announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ: URGN) on behalf of investors who purchased securities between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen failed to conduct a proper trial for its lead drug candidate, UGN-102, as the FDA questioned the sufficiency of study data due to the lack of a concurrent control arm. This led to significant stock price drops following an FDA briefing document and an Oncological Drugs Advisory Committee vote against approving UGN-102.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Wildcat Capital Management, the family office of billionaire investor David Bonderman, sold its entire 495,606 shares of UroGen Pharma (NASDAQ:URGN) in Q3, a position valued at an estimated $6.79 million. This full exit occurred despite UroGen Pharma's shares rallying over 100% in the past year. The move is viewed as disciplined capital recycling rather than a vote of no confidence, reflecting the firm's long-term investment strategy.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Wildcat Capital Management, a New York City-based billionaire family office, has fully exited its position in UroGen Pharma Ltd. (NASDAQ:URGN) by selling all 495,606 shares. This move, representing a net position change of approximately $6.79 million, followed a roughly 100% rally in UroGen Pharma's stock. The liquidation was disclosed in a November 13 SEC filing, indicating a significant portfolio adjustment for Wildcat.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Wildcat Capital Management, a family office tied to billionaire David Bonderman, sold its entire stake in UroGen Pharma (NASDAQ:URGN) in Q3, valued at $6.79 million. This full exit came after UroGen Pharma's stock rallied over 100% in the past year, reflecting Wildcat's disciplined capital recycling approach. The company specializes in treatments for urothelial and specialty cancers, with its lead product Jelmyto and a strong pipeline.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Wildcat Capital Management, the family office of billionaire David Bonderman, has sold its entire stake in UroGen Pharma Ltd. (URGN), liquidating 495,606 shares worth an estimated $6.79 million. This full exit follows a significant 113% rally in UroGen Pharma's stock over the past year, far outperforming the S&P 500. The move is viewed not as a vote of no confidence, but as a disciplined capital recycling strategy by the historically concentrated investment firm.
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC significantly increased its stake in Urogen Pharma (NASDAQ:URGN) during Q2, now owning 94,309 shares valued at approximately $1.29 million, contributing to institutional investors holding 91.29% of the stock. Despite a recent EPS beat, the company missed revenue estimates and remains unprofitable with negative margins. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $32, even as insiders have been selling shares.
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages
Urogen Pharma (NASDAQ:URGN) has received an average rating of "Moderate Buy" from brokerages, based on nine analyst reports. The company has an average 12-month price target of $32.00. Despite recent insider selling, institutional investors hold a significant portion of the company's stock.
Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN
Acorn Capital Advisors LLC reduced its stake in Urogen Pharma (NASDAQ:URGN) by 16.9% in the second quarter, now holding 1,259,749 shares valued at $17.26 million, making it their second-largest holding. Despite this, other hedge funds increased their positions, and institutional investors own 91.29% of the company. Analysts have a consensus "Moderate Buy" rating for Urogen Pharma with an average target price of $32.00.
Urogen Pharma $URGN Shares Purchased by Diadema Partners LP
Diadema Partners LP significantly increased its stake in Urogen Pharma (NASDAQ:URGN) in Q2, now owning 150,000 shares valued at $2.06 million, contributing to institutional ownership of over 91%. Despite some insider selling, analysts maintain a "Moderate Buy" consensus with an average price target of $32, while the company reported a quarterly EPS loss that beat estimates but missed revenue expectations. The stock currently trades around $22.70 with a market capitalization of $1.06 billion.
Urogen Pharma milestone: first patient treated with new cancer medication
Urogen Pharma has achieved a significant milestone by administering its novel medication to the first patient at Astera Urology for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This step highlights the company's dedication to addressing critical unmet medical needs through innovative research. Dr. Adam Berman led this pioneering treatment, which could potentially advance future cancer therapeutics.
